Spot.bz | Connect and Share

On May 11, 2006, the FDA accepted a new form of treatment in the struggle against smoking related deaths and disease. In an attempt to help smokers in the termination of cigarette smoking, the FDA has accepted Chantix tablets as a new type of cure in the fight to relieve withdrawal symptoms of smoking cessation. With suitable quantity, checking of contraindications and knowledge of side effects, you may very well have found the solution to a less shocking and upsetting process in the effort to cease smoking.

Chantix, a product of Pfizer, was accepted by the FDA on May 11, 2006. Planned to help a smoker in the termination of cigarette smoking, Chantix will not be accessible in a generic form for rather some time however; the efficiency may be well worth the price involved with a brand name drug purchase. Chantix works through binding to the brain receptors set in motion during cigarette smoking. In doing so, a small amount of nicotine is on the loose which, in turn, excites the “reward pathway” in the brain. The benefit is in the medication’s ability to relieve symptoms of withdrawal as well as acting on the sites of the brain to avoid release ”reward pathway” chemicals related with cigarette smoking.

Dosing of Chantix tablets will differ depending on the requirement of the patient. However, the FDA is counseling a dosing in a 12 week program with an expansion of an additional 12 weeks, as desirable. Physical nicotine addiction is reportedly a primary reason smokers prefer to go on with smoking. With the body’s repeated addiction to nicotine, smokers discover the withdrawal symptoms to be the most important reason to stay away from cessation. For those provoked to give up smoking, Chantix will make accessible the paybacks of decrease in the withdrawal symptoms.